Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: MR-guided tenecteplase in acute mild disabling ischemic stroke (4.5–24h)
ChiCTR2400083334Phase 4Not yet recruiting
- Sponsor
- Suzhou Science and Technology Town Hospital
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of tenecteplase in ischemic stroke (2 arms), sponsored by Suzhou Science and Technology Town Hospital. Primary endpoint: Percentage of good 90-day outcomes. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400083334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083334.